AC Immune SA discovers, designs, and develops medicines and diagnostic products. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical prevention trial for the treatment of Alzheimer's disease. It is also developing ACI-24, an anti-Abeta vaccine candidate, as well as completed Phase Ib clinical study for Down syndrome. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases.
Market Cap | 203.032 Million | Shares Outstanding | 83.552 Million | Avg 30-day Volume | 228.196 Thousand |
P/E Ratio | 0.0 | Dividend Yield | 0.0 | EPS | -0.97 |
Price to Revenue | 21.345 | Debt to Equity | 0.0083 | EBITDA | -67.577 Million |
Price to Book Value | 1.5286 | Operating Margin | -396.99309999999997 | Enterprise Value | 118.857 Million |
Current Ratio | 16.534 | EPS Growth | -2.344 | Quick Ratio | 16.138 |
1 Yr BETA | 1.2433 | 52-week High/Low | 4.93 / 1.68 | Profit Margin | -401.2767 |
Operating Cash Flow Growth | -217.7051 | Altman Z-Score | 8.8003 | Free Cash Flow to Firm | -52.357 Million |
Earnings Report | 2023-03-22 |
Please sign in first
none
none
none
Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
---|
Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
No current insider transactions |
* -
Code | Definition |
---|---|
A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
C | Conversion of derivative security |
D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
G | Bona fide gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
J | Other acquisition or disposition |
L | Small acquisition under Rule 16a-6 |
M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
O | Exercise of out-of-the-money derivative security |
P | Open market or private purchase of non-derivative or derivative security |
S | Open market or private sale of non-derivative or derivative security |
U | Disposition pursuant to a tender of shares in a change of control transaction |
W | Acquisition or disposition by will or the laws of descent and distribution |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
---|---|---|---|---|
AC IMMUNE SA ACIU | 2023-02-03 22:15:03 UTC | 0.5679 | 4.0021 | 90000 |
AC IMMUNE SA ACIU | 2023-02-03 21:45:03 UTC | 0.5679 | 4.0021 | 90000 |
AC IMMUNE SA ACIU | 2023-02-03 21:15:03 UTC | 0.5679 | 4.0021 | 90000 |
AC IMMUNE SA ACIU | 2023-02-03 20:45:06 UTC | 0.5679 | 4.0021 | 90000 |
AC IMMUNE SA ACIU | 2023-02-03 20:15:04 UTC | 0.5679 | 4.0021 | 90000 |
AC IMMUNE SA ACIU | 2023-02-03 19:45:03 UTC | 0.5679 | 4.0021 | 90000 |
AC IMMUNE SA ACIU | 2023-02-03 19:15:04 UTC | 0.5679 | 4.0021 | 90000 |
AC IMMUNE SA ACIU | 2023-02-03 18:45:03 UTC | 0.5679 | 4.0021 | 90000 |
AC IMMUNE SA ACIU | 2023-02-03 18:15:03 UTC | 0.5679 | 4.0021 | 90000 |
AC IMMUNE SA ACIU | 2023-02-03 17:45:03 UTC | 0.5679 | 4.0021 | 90000 |
AC IMMUNE SA ACIU | 2023-02-03 17:15:04 UTC | 0.5679 | 4.0021 | 90000 |
AC IMMUNE SA ACIU | 2023-02-03 16:45:04 UTC | 0.5679 | 4.0021 | 90000 |
AC IMMUNE SA ACIU | 2023-02-03 16:15:03 UTC | 0.5679 | 4.0021 | 90000 |
AC IMMUNE SA ACIU | 2023-02-03 15:45:03 UTC | 0.5679 | 4.0021 | 55000 |
AC IMMUNE SA ACIU | 2023-02-03 15:15:03 UTC | 0.5679 | 4.0021 | 55000 |
AC IMMUNE SA ACIU | 2023-02-03 14:45:04 UTC | 1.4754 | 2.8446 | 50000 |
AC IMMUNE SA ACIU | 2023-02-03 14:15:04 UTC | 1.4754 | 2.8446 | 50000 |
AC IMMUNE SA ACIU | 2023-02-03 13:45:03 UTC | 1.4754 | 2.8446 | 50000 |
AC IMMUNE SA ACIU | 2023-02-03 13:15:03 UTC | 1.4754 | 2.8446 | 50000 |
AC IMMUNE SA ACIU | 2023-02-03 12:45:03 UTC | 1.4754 | 2.8446 | 45000 |
Holder | Issuer | Net Short Position | Position Date | Origin |
---|---|---|---|---|
Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund | ACIU | -600.0 shares, $-1896.0 | 2022-09-30 | N-PORT |